CD274 and gastric cancer: To the best of our knowledge, our meta-analysis is the most accurate and adequate research, and it includes the most recent RCTs, to provide guidance on better identifying patients with GC/GEJC probably benefiting from PD-1/PD-L1 inhibitors.